Use of a PGRN inhibitor in addition to anti-hormonal agents or chemotherapy could provide a new therapeutic approach for treatment and overcome drug-resistance in patients with breast cancer who are undergoing adjuvant, neoadjuvant or palliative treatment. Here, GRN is linked to breast carcinoma.